



Gubra - Extraordinary general meeting

Today, at 10:00 CET, Gubra A/S ("**Gubra**") held an extraordinary general meeting at Plesner Advokatpartnerselskab, Amerika Plads 37, DK-2100 Copenhagen.

All proposals presented to the general meeting were adopted:

Item 1

Election of Monika Leesl and Astrid Haug as new members to the board of directors.

The board of directors hereafter consists of Jacob Jelsing (chair), Alexander Thomas Martensen-Larsen (deputy chair), Henriette Rosenquist, Arndt Justus Georg Schottelius, Monika Lesl and Astrid Haug.

Item 2

Authorization to file and register the adopted resolution with the Danish Business Authority.

Contacts at Gubra

Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586

Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra

Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Attachments

[Gubra - Extraordinary general meeting](#)